Usana Health Sciences, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 26, 2026): revenue of $205.9 million (-3.6% year over year) and diluted EPS of -$0.30. It usually reports 9–38 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Jan 2, 2027. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–38 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
38 days after quarter end
From press release
|
Q3 FY2026
ended Sep 26, 2026
|
206
-3.6%
|
-6
+14.8%
|
-0.30
+16.7%
|
|
Aug 4, 2026
31 days after quarter end
|
Q2 FY2026
ended Jul 4, 2026
|
223
-5.3%
|
-21
-321.5%
|
-1.16
-323.1%
|
|
May 5, 2026
31 days after quarter end
|
Q1 FY2026
ended Apr 4, 2026
|
250
+0.3%
|
8
-20.1%
|
0.41
-16.3%
|
|
Jan 12, 2026
9 days after quarter end
|
Q4 FY2025
ended Jan 3, 2026
|
226
|
-2
|
-0.10
|
|
Oct 9, 2025
12 days after quarter end
|
Q3 FY2025
ended Sep 27, 2025
|
214
+6.7%
|
-7
-161.5%
|
-0.36
-164.3%
|
|
Jul 22, 2025
24 days after quarter end
|
Q2 FY2025
ended Jun 28, 2025
|
236
+10.8%
|
10
-7.4%
|
0.52
-3.7%
|
|
Apr 22, 2025
24 days after quarter end
|
Q1 FY2025
ended Mar 29, 2025
|
250
+9.5%
|
9
-43.1%
|
0.49
-43.0%
|
|
Feb 25, 2025
59 days after quarter end
|
Q4 FY2024
ended Dec 28, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- USNA (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 896264
- Former names
- USANA INC (until Apr 27, 2000)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.